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Abstract
Purpose To determine whether an optimal method exists
for the detection of the luteinising hormone (LH) surge
onset in research datasets of urinary hormonal profiles of
menstrual cycles.
Methods The scientific literature was searched to com-
pare published methodologies for detection of the LH surge
onset in urine. Their performance was tested using com-
plete hormonal profiles from 254 ovulatory cycles from
227 women attempting pregnancy (normal regular men-
strual cycles; no known infertility).
Results Three major methodologies to determine the on-
set of the LH surge in urine were identified. The key dif-
ference between these methods is how the cycle days that
contribute to LH baseline assessment are determined: using
fixed days (method #1), based on peak LH day (method
#2), based on a provisional estimate of the LH surge
(method #3). Method #1 requires no prior cycle informa-
tion, whereas methods #2 and #3 need to consider complete
cycle data. The most reliable method for calculation of
baseline LH was using 2 days before the estimated surge
day, plus the previous 4/5 days.
Conclusions Different methods for identification of the
urinary LH surge can provide very different determinations
of LH surge day, thus care must be taken when comparing
between studies that apply different methodologies. The
optimal method for determining the onset of the LH surge
in urine requires retrospective estimation of day of LH
surge to identify the most appropriate part of the cycle to
consider as the baseline. This method can be adopted for
application in population studies.
Keywords Luteinising hormone  LH  LH surge 
Menstrual cycle
Introduction
Luteinising hormone (LH) plays a complex role in human
ovarian physiology. During the follicular phase, it stimu-
lates thecal cells to produce androgens, which are con-
verted into oestrogens by the granulosa cells. During the
luteal phase, LH has a major role in maintaining the full
function of the corpus luteum. However, regarding fertility
control, its most significant role is to induce ovulation at
mid-cycle [1]. During ovulation, LH triggers the comple-
tion of the maturational process of the oocyte to metaphase
II, and its release from the follicle. Finding reliable ways to
determine the moment of ovulation is a critical task in the
control of human conception and contraception. It also has
implications in reproductive medicine, such as timed in-
tercourse, artificial insemination and the diagnosis of
anovulation [2].
Understanding the underlying population variability
with regard to ovulation is extremely important to appro-
priately design methodologies to prospectively predict
ovulation; for example, for the purposes of timing inter-
course to achieve pregnancy. The measurement of repro-
ductive hormones in daily urine samples during the
menstrual cycle, especially LH, combines an easy way to
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collect specimens, and an objective reference to determine
the onset of ovulation.
The level of LH suddenly surges, then peaks mid-cycle
causing the dominant follicle to rupture and release a
mature ovum. Ovulation typically occurs approximately
28–48 h after the beginning of the LH surge [3] and ap-
proximately 0.5 days after the peak in levels of LH [4].
Determination of peak LH is simple, but as peak urinary
LH levels coincide with, or occur after ovulation, calcu-
lation of the peak LH day does not provide the advanced
warning of ovulation that is needed for timing of inter-
course, or fertility procedures [3, 5, 6]. In addition, urinary
peak LH day can differ according to the assay used to
measure LH in urine, with those detecting beta-core LH
(LH-bc) identifying a peak day at least 1 day after assays
that do not detect LH-bc [4]. Identification of the day of the
urinary LH surge does not appear to be influenced by the
assay used, and provides 24–36 h warning of impending
ovulation [7–10], therefore making it an excellent pa-
rameter to measure in order to provide prospective infor-
mation regarding ovulation. Therefore, it is important to
have a well-validated method for assignment of the LH
surge and to examine retrospective datasets to provide in-
formation on population variability of LH surge.
Detecting the day of the LH surge in urine, when the first
sustained rise in the level of this hormone occurs, is not
straightforward. The onset of the LH surge in women of
reproductive age has been investigated by many researchers,
who have developed different approaches for surge identi-
fication [3, 6, 7, 10–18]. Nevertheless, no comparison has
been made between these different methods to date, to de-
termine whether they are equally valid, or whether there is
one method that is more effective than the others.
The aim of this study was to compare the different
methods reported in published studies that have been devel-
oped to estimate the onset of the LH surge in urine during the
menstrual cycle. The study sought to identify the different
methods used, and subsequently compare them on a suffi-
ciently large number of complete LH profiles from ovulatory
cycles of premenopausal fertile women, to determine the most
appropriate method to use for the retrospective analysis of
study populations. The results of these analyses will lead to
further understanding of LH profiles in women and may assist
in improving the accuracy of prospective methods of pre-
dicting ovulation based on the detection of the LH surge.
Methods
Selection of peer-reviewed papers
To identify published methods used to detect the onset of
the LH surge in urine during the menstrual cycle, a
thorough search of the scientific literature of peer-reviewed
papers in biomedical journals was completed. PubMed and
Web of Science databases were searched using the fol-
lowing terms: LH (all spelling variations and abbre-
viations); surge (all equivalent terms e.g. rise, increase).
All abstracts were examined and full papers obtained if the
LH surge (or equivalent) was a parameter measured in the
study. Citations within identified papers were also inves-
tigated to identify further relevant papers. Out of these
studies, only those in human subjects describing full
methodologies to detect the LH surge during the menstrual
cycle were selected for inclusion in this analysis.
Testing the methodology
From the selected studies, the algorithms employed to
detect the LH surge in each case were investigated, the
methodology was compared, and a classification of the
different methods was established. The identified methods
were then compared by analysing their performance in
complete urinary hormonal profiles of a reliable sample of
menstrual cycles.
Menstrual cycle collection
Complete menstrual profiles (from menses to menses) of
urinary levels of LH and pregnanediol-3-glucuronide
(PdG) were used to compare the different methods de-
signed for detecting the LH surge during the cycle. Daily
urine samples (first morning void) were collected by 227
premenopausal women, aged 18–45 years, attempting to
become pregnant, with regular cycles of normal duration
(21–42 days), and no known fertility problem. Volunteers
were required to have two natural cycles prior to study
entry and could not be using any fertility medications,
breast feeding or have diagnosed polycystic ovarian syn-
drome. The volunteers collected daily urine samples into
sample pots containing sodium azide as a preservative.
Volunteers were required to refrigerate samples on col-
lection and return them to the study site, where samples
were frozen at -80 C prior to analysis.
Sample analysis
Hormone analyses were conducted as batch analyses, en-
suring complete cycles were analysed on single assay
plates. Samples were brought to room temperature and
mixed prior to analysis. It had previously been determined
that up to five freeze–thaw cycles had no effect on analyte
concentration.
Hormonal analysis of urinary LH and PdG was con-
ducted using AutoDELFIA (Perkin Elmer, Waltham, USA)
as previously described [19]. The in-house LH assay
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consists of immobilised biotinylated antibody (antibody
#2119; SPD Development Co., Ltd, Bedford, UK) that
recognises the alpha LH subunit bound to streptavidin
plates, and a second, europium-labelled antibody that
recognises the beta subunit (antibody #2301; SPD Devel-
opment Co., Ltd, Bedford, UK), thus it is only able to
measure intact LH. Assay sensitivity was 0.1 mIU/ml and
inter- and intra-assay percentage coefficient of variation
(CV) was less than 5 %; linearity was seen in dilutions up
to 1 in 20 and no high-dose hook was observed when
testing up to 1000 mIU/ml. The PdG assay used was also
an in-house competitive immunoassay based on competi-
tion between sample and europium-labelled PdG for
binding by a high-affinity antibody (antibody #5806; SPD
Development Co., Ltd, Bedford, UK). Assay sensitivity
was 0.021 lg/ml and intra- and inter-assay percentage CV
was below 10 % for the standards tested (0.16, 0.80, 4.00,
20.00, 100.00 lg/ml); linearity was seen in up to a 1 in 20
dilution of urine sample.
Cycle inclusion and analysis of methods identified
in the literature for determining the urinary LH
surge
A total of 254 reference cycles with complete hormonal
profiles of LH and PdG were included in this study. Out
of these cycles, 148 ended in conception. Only hormonal
profiles showing these unambiguous features of ovulation
were included in the study. The existence of the LH
surges followed by peaks, as well as a consistent rise in
the levels of PdG, was proved visually on the plotted
hormonal profiles (LH and PdG). The LH surge day was
assigned following abundant visual analysis of the gra-
phical data by the authors. This method has been shown
repeatedly to be effective and reliable in the interpretation
of basal body temperature charts for assigning reference
point in menstrual cycles [20, 21]. LH and PdG profiles
corroborate the correctness of this visually assigned LH
surge; rise of urinary LH surge occurs 0.81 ± 0.89 days
prior to ovulation and the rise of urinary PdG from
baseline has been demonstrated to occur 3.20 ± 1.07 days
after ovulation (Roos et al., submitted), using the assay
previously reported and employed [4]. This LH surge was
considered the reference surge day against which mod-
elled surges were compared for agreement. The algo-
rithms defined by each method were evaluated in the
cycles using SAS 9.3 software. LH baseline was deter-
mined for each method for each cycle, then surge as-
signed for each method identified in the literature. The
surge was determined as the first sustained rise in LH
above the baseline, with a sustained rise defined as a level
of at least 2.5-fold of the standard deviation (SD) over the
mean baseline level.
Agreement between the reference surge and the results
from the modelled surges from the different literature-
identified methods were examined to the exact day.
Results
Analysis of the scientific literature
Altogether, 12 studies investigating the onset of the LH
surge in the menstrual cycle, containing a well-defined,
reliable, methodology for detecting the surge in urine were
identified (Table 1) [3, 6, 7, 10–18]. From the methodology
described in these 12 studies, 16 different methods used for
detecting the LH surge were identified. Analysis of these
16 methods found that they could be separated into three
major methodological categories.
All the identified methods defined the LH surge as ‘the
first sustained rise in the level of LH, from the first day of
the cycle’. Similarly, all methods used the mean value of 4
or 5 days to estimate baseline LH values.
The definition of the magnitude of the rise in the level of
LH to identify the occurrence of the surge was defined
differently in the various studies. Some studies took a
multiple value of the baseline level (e.g. twice or three
times the baseline level), others considered it as a number
of SD values over the mean baseline level.
However, the key difference between the algorithms
developed is the method used to determine the baseline
level of LH during the follicular phase of the cycle from
where the rise occurs and, specifically, the reference points
used to estimate this baseline value.
Methods identified for the detection of the onset
of the LH surge in the menstrual cycle
Three major categories of methods, based on estimation of
the baseline values of urinary LH can be distinguished:
1. Using fixed days during the cycle. The basal level of
urinary LH is determined by calculating the mean LH
value from day 5 (or 6) of the cycle, and up to days 8, 9
or 10. Four different variations of this method have
been used: mean LH levels from days 5 to 8, from days
5 to 9, from days 6 to 9 and from days 6 to 10. This
method can be applied both retrospectively and
prospectively, as it does not need data of the complete
menstrual cycle.
2. Using the day of the LH peak in the cycle. Urinary LH
peak day of the cycle under investigation is identified,
then 3, 4, 5 or 6 days prior to this is taken as a
reference day, and the mean LH value on the reference
day is then calculated, plus the level on the previous 3
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or 4 days. In total, eight variations of this method were
observed; estimating the mean LH value of, either, the
previous 3 or 4 days plus the reference day, which are
days 3, 4, 5 or 6 before the day of the LH peak. This
method can only be applied retrospectively as data
from the complete menstrual cycle are necessary for its
application.
3. Using an estimate of the LH surge. This approach
makes a rough estimation of the day of urinary LH
surge by examination of the data of the cycle under
investigation. It then takes days 1 or 2 before the
estimated LH surge, as a reference level, plus the level
on the previous 3 or 4 days, to calculate the mean value
of LH. Four variants of this approach are documented.
This method also can only be applied retrospectively as
it requires data from the complete menstrual cycle.
Comparison of the methods used to determine
baseline value of LH
For all of the methods identified above, the baseline LH
level was calculated. The method-dependent surge was
then determined as the first sustained rise in LH above the
baseline, with a sustained rise defined as a level of at least
2.5-fold of the SD over the mean baseline level. Figure 1
shows an example of complete hormonal profiles of LH
during the menstrual cycle, highlighting the references
used by each of the methods to determine the baseline
value of LH in the follicular phase of the cycle.
Performance of the identified methods
for identifying the LH surge in complete urinary
hormonal profiles of a reliable sample of menstrual
cycles
Table 2 shows the results of the analysis evaluating the
performance of all the different methods identified in the
scientific literature for determining the onset of the LH
surge in the 254 complete hormonal profiles analysed,
whereby the surge day calculated by the various methods
identified in the literature was compared with the reference
surge day (as determined by an examination of the gra-
phical cycle images by an expert panel).
Method category 1 based on fixed days to estimate
the baseline levels of LH
Four variants are reported in the literature that use fixed
days during the cycle to estimate baseline urinary LH
levels. These methods provided correct surge detection in
44.5–52.8 % of cycles (dependent on exact method). The
values obtained for each specific method were: 44.5 %
when using cycle days 5–8; 48.4 % when using days 5–9;
48.0 % when using days 6–9; 52.8 % when using days
6–10. The performance of these methods for identifying the
surge on ±1 day of the reference surge ranged between
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Fig. 1 Application of methods to determine baseline for LH surge
identification to an example menstrual cycle. Each individual method
is numbered: a using fixed days to calculate baseline, b using LH peak
to calculate baseline, c using estimated LH surge to calculate baseline
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Method category 2 based on the day of the LH peak
to estimate baseline LH levels
When the reference to determine the baseline values was
the urinary LH peak, the approaches identified performed
better than the fixed days method, detecting 63.4–70.5 %
of the surges correctly, depending on which set of the eight
variants of this category were applied.
When the reference was taken on day 3 before the LH
peak, plus the previous 3 days to determine baseline values,
the surge was correctly identified in 63.4 % of the cases;
however, when it was day 3 before the peak plus the pre-
vious 5 days, it was identified correctly in 65.4 % of cases.
When the reference started on day 4 before the peak plus
the previous 3 days, the surge was correctly identified in
70.5 % of cases, and if taking the previous 4 days instead,
it correctly identified 68.5 % of the cases. When the ref-
erence was day 5 before the peak, plus the previous 3 days,
it correctly identified the surge in 67 % of the cases,
whereas if it took the previous 4 days instead, it correctly
identified 64.6 % of the cases.
Finally, when the reference started on day 6 before the
peak, plus the previous 3 days, it correctly identified the
surge in 59.1 % of the cases, whereas when taking the
previous 4 days it correctly identified 60.2 % of cases.
When considering the performance at determining the surge
±1 day of the reference surge, the range rose to 73.3–90.5 %.
Method category 3 based on the day of the LH surge
to estimate baseline LH levels
Methods using the estimated urinary LH surge as a refer-
ence to determine the baseline LH value were observed to
offer superior performance in correctly detecting the surge,
finding them correctly ranged from 74.4 to 78.4 %.
When the reference to estimate baseline values started
from day 1 before the estimated surge plus the previous
3 days, it correctly identified the surge in 78.4 % of the
cases, whereas taking the previous 4 days instead identified
76.4 % of the surges correctly. When the reference used
was day 2 before the estimated surge plus the previous
3 days, it correctly identified 74.4 % of the cases, whereas
using 4 days, produced 75.2 % of correct identifications.
The performance of these methods at finding the surge
within ±1 day of the reference surge ranged from 94.5 to
97.6 %.
Discussion
Prediction of ovulation can be important for women who
are trying to conceive, in order for them to time intercourse
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conception. It can also have clinical importance for ap-
propriate timing of procedures, such as intrauterine in-
semination, frozen embryo transfer or donor sperm
insemination.
Over the years, several methods have been developed to
predict ovulation. One of the most common methods used
in fertility awareness is the sympto-thermal method (STM)
because abundant evidence of its reliability has been pre-
sented [22–25]. However, the STM requires training in use,
detailed recording of symptoms of self-observation and the
application of several calculation rules, all lowering gen-
eral acceptance rates. With the advancement of technology,
other reliable, objective and less user-dependent methods
have been introduced, which rely on the analysis of the
levels of reproductive hormones measured in urine [26].
The study of hormonal profiles in urine during the men-
strual cycle has proved to be very valuable in under-
standing menstrual cycle dynamics, as well as variability in
ovulation [19, 27, 28]. Likewise, urinary hormone testing
has become an established application for personal
monitoring of fertility awareness [9]. Both temperature and
hormonal analysis using repeated measurements in men-
strual cycles are currently under intensive research as part
of the evolving field of digital signal tracking in gynae-
cological endocrinology [21].
In premenopausal women, the menstrual cycle has a
recognisable general pattern, and an average duration;
however, there are important variations in cycle length and
dynamics, both between and within women [29–33].
Likewise, there are differences in hormonal patterns, even
in ovulatory cycles, which introduce a further source of
difficulty into the analysis [34, 35]. This compromises the
utility of all fertility awareness methods that solely rely on
statistical parameters or calculation rules of the menstrual
cycle (i.e. monitoring cycle days), and strengthens the
importance of looking at specific events of physiological
relevance leading to ovulation, such as the LH surge. It is
the LH surge which always precedes ovulation, rather than
the LH peak, and which is a signal of impending ovulation
and peak fertility. Therefore, it is important to have a re-
liable algorithm to determine the onset of the LH surge in
population studies. A standardised algorithm for deter-
mining the timing of the urinary LH surge in studies that
have examined the hormone profiles in women is still not
available.
This study examined the scientific literature, searching
for studies focusing on the detection of the onset of the LH
surge during the cycle, in urine samples, and found 12
relevant studies. In these papers, there were three major
methodological categories designed and used to determine
the onset of the surge. The key difference between these
methods was the reference used for estimating the baseline
values of urinary LH during the follicular phase. Important
differences in the performance of these methods were
identified. Methods that used the LH surge as a reference to
estimate baseline values of LH clearly had the highest level
of reliability in this respect, detecting on average up to
76.1 % of the surges, compared with only 64.8 % when the
LH peak was used as a reference and 48.4 % when using
fixed days of the cycle. The findings of this study might help
to improve the analysis of the human menstrual cycle for
monitoring to assist with conception and contraception, as
well as for biomedical research. In addition, a common
methodology would facilitate comparisons between studies.
Many studies report LH peak [29, 36]; however, as a
prospective measure, peak LH has less value as it often
occurs post ovulation [37]. In addition, assignment of the
day of peak urinary LH is dependent on the assay used [4].
Some urinary LH assays use antibodies that recognise the
beta-core fragment of LH (LH-bcf), which is a by-product
of LH metabolism, and the predominant molecular form of
LH in the urine [38]. Levels of LH-bcf continue to rise
after the level of the physiologically relevant intact LH
reaches peak concentration, sometimes achieving maximal
levels up to 5 days later [4].
The comparatively poor performance of this prospec-
tively applicable approach that uses fixed days during the
menstrual cycle to determine baseline levels of LH is
somewhat expected, since this approach does not take into
consideration important factors, such as the variability in
the length of the cycle, which mostly affects the follicular
phase and exerts an influence over the hormonal dynamics
[30]. Ovulation has been seen as early as day 8 of the
menstrual cycle and, as the fixed days method generally
includes day 8, it is clear that this method will fail under
such circumstances.
The higher reliability of a mid-cycle reference (method
#2) to determine baseline LH was anticipated, because data
from the complete menstrual cycle have to be considered
for its application, and due to its proximity with the fertile
window, which is a very stable stage of the cycle, and
unlike the early follicular phase, is not affected by age [39,
40]. It is also clear why the approach that uses the esti-
mated surge (method #3) as a reference performs better
than the method using the peak (method #2) because in
almost 25 % of normal menstrual cycles the peak may
occur postovulatory (Roos et al. submitted); differences in
the LH dynamics around the time of the surge and peak in
LH account for this. Some complex LH peaks have been
described when researchers have used an assay that
recognises LH-bcf, with a longer duration than normal,
sometimes described as ‘biphasic’ or in ‘plateau’ [6, 11];
this often presents a significant delay between the surge
and the peak of LH, compared with the ‘spike’ type of
peaks. It is possible that when the reference is taken
starting 3 or 4 days before the peak, in this type of cycle,
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levels of LH are already high, decreasing the accuracy of
the estimation of the baseline levels. Likewise, when using
a large number of days away from the peak (such as 6 or 5),
in short cycles or those of normal duration, the levels es-
timated might be closer to those found in the fixed
approach.
For fertility monitors, however, a retrospective approach
with analysis of data from a complete menstrual cycle is
not applicable. Therefore, learning monitors should con-
sider the location reference points from previous cycles for
higher reliability of surge detection. Current research fo-
cuses on a formal mathematical approach (signal tracking),
finding distinct patterns in hormonal and temperature
curves to predict change points and distinguish them from
the random ‘noise’ (change-point analysis) [21].
A further way to improve the results includes other
hormonal markers in urine, in addition to LH. These are
estradiol and its metabolites, since a rise in the levels of
estradiol triggers the rise in the levels of LH [38], and peak
estrone-3-glucuronide (E3G) levels occur on the day of
ovulation, as do those of follicle-stimulating hormone
(FSH). However, this level of detail would add consider-
able complexity and additional cost to the analysis, espe-
cially by repeated measurement.
Ultrasound-observed ovulation is the gold-standard
method used to determine the timing of ovulation and it
would be of interest to observe how different approaches to
LH surge definition compare to this reference. However,
there is variability between women in the timing of the LH
surge in relation to ultrasound-observed ovulation [6], thus
further work could consider this relationship.
In conclusion, this study found that there are many
methods for calculating the LH surge in urine reported in
the literature, and their effectiveness at correctly identify-
ing the surge varies between methods. Some of these
methods are in use in current fertility monitors. Care
should be taken when comparing between studies reporting
urinary LH surge data, as results will be dependent on the
method employed for surge identification. This study sup-
ports the recommendation for using methods that involve
an initial estimation of the LH surge to establish which
days should be used to determine baseline.
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